Peng Wu

Forschungsgruppenleiter
Protein-RNA Interactions and Post-Transcriptional Modulations

Vita

Current Positions

2024 – now     Substitute Chair/W3 Professor
                           Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany

2018 – now     Group Leader
                           Chemica Genomics Centre, Max Planck Institute of Molecular Physiology, Dortmund, Germany

 

Previous Positions

2018                Assistant Professor
                         Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

2016-2018      Postdoc/Research Fellow
                         Department of Medicine/Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
                         Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, USA
                         Department of Chemistry, Massachusetts Institute of Technology, Cambridge, USA

2012-2016      Postdoc
                         Department of Chemistry, Technical University of Denmark, Lyngby, Denmark
                         Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

 

Dr. Peng Wu received his Doctoral Degree in Medicinal Chemistry from Zhejiang University in 2012. He then performed postdoctoral research at the Technical University of Denmark and the University of Copenhagen. In 2016, he moved to Cambridge, MA, working as Research Fellow in Chemical Biology at Harvard, Broad Institute, BWH, and MIT. In Mar. 2018, he was appointed as Assistant Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen. Since Oct. 2018, he has been Group Leader at the Chemical Genomics Centre of the Max Planck Institute of Molecular Physiology in Dortmund. Starting from Apr. 2024, he is the Substitute Chair and W-3 Professor in Chemical Biology at the TU Dortmund University. His research interest originates from the interface between chemistry and biology. A central theme of his research projects is to develop new small molecule-based modulators and novel chemical modalities to target biological macromolecules, especially RNA-binding proteins and disease-associated RNAs.